NORAD and breast cancer: Considering all breast cancer subtypes as a group, NORAD levels do not correlate with relapse-free survival (n = 2032, p = 0.057) (Figure 1D) nor overall survival (n = 943, p = 0.25) (Figures S1A and S1B).